Vitadio develops prescription digital therapeutics (DTx) that target the causes of cardiometabolic disease by combining AI-driven lifestyle modification with evidence-based medical content. The company focuses on reversing insulin resistance through personalised daily guidance and real-time diet feedback.

Vitadio's product is a Class I medical device under MDR and is ISO 27001 and GDPR compliant. Multiple independent, peer-reviewed studies report significant improvements in HbA1c, weight reduction, and diabetes self-management when using the therapy.

Vitadio is the first digital therapy for type 2 diabetes covered by statutory health insurers in Germany and works with large pharmaceutical and payer partners to augment pharmacotherapy and improve patient outcomes.

Founded in 2019, Vitadio is headquartered in Prague and Berlin and provides digital therapeutics for type 2 diabetes and prediabetes across several European countries. The team aims to empower people to restore cardiometabolic health, one habit at a time, with scalable digital care.

Vitadio is hiring and maintains an open careers page with current openings. The company provides in-app human support including dietitians and an in-app social network to maximise long-term engagement.